Compare IMNM & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMNM | HRMY |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2020 | 2020 |
| Metric | IMNM | HRMY |
|---|---|---|
| Price | $19.42 | $39.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 9 |
| Target Price | $26.89 | ★ $51.33 |
| AVG Volume (30 Days) | ★ 1.2M | 769.8K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | $9,679,000.00 | ★ $825,944,000.00 |
| Revenue This Year | N/A | $23.11 |
| Revenue Next Year | N/A | $16.15 |
| P/E Ratio | ★ N/A | $12.25 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $5.15 | $25.52 |
| 52 Week High | $20.46 | $40.93 |
| Indicator | IMNM | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 60.95 | 76.71 |
| Support Level | $16.81 | $32.77 |
| Resistance Level | $20.46 | $40.00 |
| Average True Range (ATR) | 1.20 | 1.23 |
| MACD | 0.03 | 0.32 |
| Stochastic Oscillator | 72.74 | 86.72 |
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.